Andrea Landorph

Soborg, 2860, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage.

Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage.

Journal: Journal of clinical medicine

Published: February 28, 2024

Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.

Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 07, 2020

Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5.

Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 07, 2020

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: September 30, 2019

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII.

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII.

Journal: Patient preference and adherence

Published: May 02, 2019

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: July 16, 2018

Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.

Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.

Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis

Published: February 18, 2015

Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease.

Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease.

Journal: Seminars in thrombosis and hemostasis

Published: November 22, 2011

Showing 1-8 of 8

Last Updated: 09/26/2026